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Background:  Hypertension and age are recognized as important risk factors for left ventricular (LV) diastolic dysfunction. Some 
studies have shown that diabetes itself may also be an independent risk factor for LV diastolic dysfunction, although this is con-
troversial. The aim of this study was to determine the factors associated with LV diastolic dysfunction in patients with type 2 dia-
betes in the absence of hypertension or ischemic heart disease (IHD).
Methods:  Participants in this study consisted of 65 type 2 diabetes patients (M : F = 45 : 20; mean age 51 [26 to 76] years; mean 
body mass index [BMI] 25.0 ± 2.5 kg/m
2) without hypertension, heart disease, or renal disease. Individuals with ischemic elec-
trocardiographic changes were excluded. LV diastolic function was evaluated by Doppler echocardiographic studies.
Results:  Fifteen patients (23.1%) showed LV diastolic dysfunction on Doppler echocardiographic studies. Patients with LV dia-
stolic dysfunction were older than those without diastolic dysfunction (60.0 ± 2.5 vs. 50.5 ± 1.9 years; P < 0.01). After adjusting 
for age and sex, BMI was higher (26.6 ± 0.7 vs. 24.6 ± 0.3 kg/m
2; P < 0.01) and diabetes duration was longer (9.65 ± 1.48 vs. 4.71 
± 0.78 years; P < 0.01) in patients with LV diastolic dysfunction than in those without diastolic dysfunction. There were no differ-
ences in sex, smoking, blood pressure, lipid profiles, hemoglobin A1C, fasting glucose, fasting insulin, or diabetic microvascular 
complications between the LV diastolic dysfunction group and the normal diastolic function group. After adjusting for age, sex, 
and BMI, diabetes duration was found to be independently associated with LV diastolic dysfunction (odds ratio 1.38; confidence 
interval 1.12 to 1.72; P = 0.003).
Conclusion:  These results suggest that diabetes duration may be a risk factor for LV diastolic dysfunction in type 2 diabetic pa-
tients without hypertension or IHD.
Keywords:  Diabetes duration; Diabetes mellitus; Left ventricular diastolic dysfunction
Corresponding author:  Dong Jun Kim
Department of Internal Medicine, Inje University Ilsan Paik Hospital,  
2240 Daehwa-dong, IlsanSeo-gu, Goyang, Gyeonggi 411-706, Korea
E-mail: djkim@paik.ac.kr
Received: May 25, 2009; Accepted: Jan. 15, 2010
INTRODUCTION
Heart failure is a common comorbidity and fatal complication 
of diabetes mellitus. The Framingham heart study demonstrat-
ed an increased risk of heart failure in patients with diabetes: a 
two-fold higher incidence in men and a five-fold higher inci-
dence in women with diabetes compared with age-matched 
non-diabetic subjects [1]. Many epidemiological studies have 
confirmed a significantly increased prevalence of cardiac dys-
function in diabetic patients, independent of the influence of 
relevant covariates [2-4]. Left ventricular (LV) diastolic dys-
function is thought be an early preclinical manifestation of 
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heart failure [5]. The incidence of diastolic dysfunction in dia-
betic patients has been demonstrated to be 30-75% in recent 
studies [6-8].
  Considering the high prevalence and significant morbidity 
and mortality of heart failure in patients with type 2 diabetes, 
identification of risk factors for LV diastolic dysfunction and 
an index of early-stage diabetic cardiomyopathy are necessary 
to delay or prevent the onset of heart failure. Age, hypertension, 
and ischemic heart disease (IHD) are thought to be important 
risk factors for diastolic dysfunction in both patients with dia-
betes and non-diabetics [9-11]. Although several studies have 
shown that poor glycemic control and longer duration of dia-
betes may be associated with early diastolic dysfunction in type 
2 diabetes [12-14], there have been few studies on the factors 
associated with LV diastolic dysfunction in type 2 diabetes with-
out hypertension or IHD. Therefore, we sought to determine 
the risk factors associated with subclinical LV diastolic dysfunc-
tion in type 2 diabetic patients without hypertension or IHD.
METHODS
Study participants
This study was approved by the Institutional Review Board of 
Ilsan-Paik Hospital. The study subjects consisted of 65 type 2 
diabetic patients without hypertension or IHD (M : F = 45 : 20; 
mean age 51 [26-76] years; mean body mass index [BMI] 25.0 
± 2.5 kg/m
2) who initially visited the outpatient diabetes clinic 
at Inje University Ilsan-Paik Hospital between January 2006 
and April 2006. Inclusion criteria were: i) normal arterial blood 
pressure (< 130/85 mm Hg) without antihypertensive medica-
tion, ii) no symptoms or signs of heart disease, iii) no history 
of coronary heart disease (stable angina, unstable angina, myo-
cardial infarction, or revascularization) or valvular heart dis-
ease, iv) sinus rhythm and no evidence of IHD on resting 12-
lead ECG, v) no evidence of severe medical illness including 
liver cirrhosis, end-stage renal disease, or cancer. Patients were 
excluded from participation in the study if either of the follow-
ing criteria applied: i) diabetes diagnosed before the age of 26, 
or ii) history of type 1 diabetes or diabetic ketoacidosis.
Data collection and clinical evaluation
Height and weight were measured in the morning with the 
subjects wearing light clothing but no shoes. Blood pressure 
was measured with a mercury sphygmomanometer on the 
right arm with the subjects in a sitting position after a 5-min-
ute rest. BMI was calculated as weight in kilograms divided by 
the square of the height in meters. Diabetes duration and dia-
betic complications were ascertained from review of medical 
records. Diabetic complications were recorded as retinopathy, 
neuropathy (absence of ankle jerks and reduced vibratory sen-
sation, or impairment on nerve conduction studies or auto-
nomic function tests), overt proteinuria (24 hour urine protein 
≥ 300 mg/day), or microalbuminuria. Fasting plasma glucose 
(FPG), total cholesterol, high-density lipoprotein (HDL)-cho-
lesterol, low-density (LDL)-cholesterol, lipoprotein a [Lp(a)], 
triglycerides, and uric acid were measured with an autoana-
lyzer (Beckman Coulter, Miami, FL, USA). Level of hemoglo-
bin A1C (HbA1C) (high performance liquid chromatography; 
Tosoh, Tokyo, Japan), serum insulin (two-site chemilumines-
cent immunometric assay; Roche, Basel, Switzerland), and high-
sensitivity C-reactive protein (hs-CRP, enzyme-linked immu-
nosorbent assay; DRG Diagnostics, Marburg, Germany) were 
also measured.
Echocardiographic study
All echocardiographic examinations were performed on a GE 
VingMed Vivid 5
® Echocardiography System (GE Medical Sys-
tems, Milwaukee, WI, USA) with a 2.5 MHz transducer. All 
smokers were prevented from smoking for at least 30 minutes 
before the examination. The examination was performed while 
the patient was in a period of quiet respiration. Echocardio-
grams were stored digitally and analyzed by one examiner. All 
recordings were performed at a high sweep speed (100 mm/
sec) with simultaneous electrocardiographic (ECG) recording 
and included complete M-mode, 2-dimensional, and Doppler 
echocardiographic examinations, with emphasis on evaluation 
of LV diastolic function [10-12]. For evaluation of diastolic 
myocardial function, mitral inflow velocities (E- and A-waves, 
cm/sec), deceleration time (DT), isovolumic relaxation time 
(IVRT), systolic (S) and diastolic (D) pulmonary venous for-
ward flow, pulmonary venous atrial reversal velocity (Ar), and 
early (E’) and late (A’) diastolic velocity of mitral annulus were 
measured in compliance with the standard protocols [10-12]. 
Left ventricular systolic function was determined by estima-
tion of left ventricular ejection fraction (LVEF). The normal 
range of LVEF was 65 ± 10%.
  The following criteria were used for the diagnosis of LV dia-
stolic function [15]: impaired relaxation pattern was defined 
as E/A ratio < 1.0 and DT > 200 ms; pseudonormal pattern as 
E/A ratio from 1.0 - 2.0 with at least two of the following: S/D 42
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ratio < 1, or Ar ≥ 35 cm/sec, or E’ < A’ and E/E’ ratio > 10; and 
restrictive pattern as E/A ratio > 2.0 and DT < 150 ms. All dia-
stolic dysfunctions in this study were impaired relaxation pat-
tern.
Statistical analysis
  Data are presented as mean ± SEM. Statistical analysis was 
performed using SPSS for Windows (SPSS Inc., Chicago, IL, 
USA). Differences in variables between patients with and 
without LV diastolic dysfunction were analyzed using Mann-
Whitney test and Fisher’s exact test. Analysis of covariance 
(ANCOVA) test was used for age and sex-adjusted character-
istics according to the presence of diastolic dysfunction (Table 
1). ANCOVA test was also used to assess the independent asso-
ciation of duration of diabetes with the presence of diastolic dys-
function, with age, sex, and BMI as covariates (Fig. 1). Logistic 
regression analysis was used to examine independent determi-
nants for diastolic dysfunction, with age, sex, BMI, and dura-
tion of diabetes as covariates. All probability values were two-
tailed, and statistical significance was defined as P < 0.05.
RESULTS
Characteristics of participants
The median duration of diabetes for the study subjects was 5 
years (range, 0 to 26). Mean HbA1C was 8.0 ± 2.1%. Fifteen pa-
Table 1.  Age, sex and age and sex-adjusted characteristics according to the presence of diastolic dysfunction in type 2 diabetic 
patients without hypertension
Normal left ventricular diastolic function
(n = 50)
Left ventricular diastolic dysfunction
(n = 15)
P value
Age, yr 51.2 ± 1.8 60.0 ± 2.5 <0.01
Men/Total 36/50 9/15 0.52
BMI, kg/m
2 24.6 ± 0.3 26.8 ± 0.8 0.01
Current smoking, % 26 20 0.74
Systolic blood pressure, mm Hg 119.9 ± 1.4 120.9 ± 2.9 0.51
Diastolic blood pressure, mm Hg 71.6 ± 1.0 72.1 ± 1.8 0.81
Pulse pressure, mm Hg 48.3 ± 1.1 48.8 ± 2.1 0.85
LDL-C, mg/dL 120.8 ± 6.2 120.6 ± 11.6 0.99
Triglyceride, mg/dL 158.2 ± 15.6 189.6 ± 29.3 0.36
HDL-C, mg/dL 41.9 ± 1.5 44.4 ± 2.9 0.46
Lp(a), mg/dL 18.5 ± 3.3 25.8 ± 6.2 0.31
Duration of diabetes, yr 4.77 ± 0.79 9.73 ± 1.49 <0.01
Fasting glucose, mg/dL 161.0 ± 6.1 157.0 ± 11.4 0.76
HbA1C, % 8.16 ± 0.29 7.63 ± 0.54 0.39
Fasting insulin, µU/mL 6.47 ± 0.65 6.79 ± 1.21 0.82
HOMA-IR 2.64 ± 0.29 2.57 ± 0.55 0.91
Diabetic retinopathy, % 14.4 ± 5.6 32.1 ± 10.4 0.15
Overt proteiunuria, % 4.0 13.3 0.23
Microalbuminuria, % 8.0 13.3 0.33
Diabetic neuropathy, % 8.0 20.0 0.13
WBC, /mm
3 6,110 ± 288 7,141 ± 557 0.11
hs-CRP, mg/L 0.59 ± 0.41 0.33 ± 0.78 0.77
Uric acid, mg/dL 4.71 ± 0.19 5.37 ± 0.36 0.12
Data are expressed as mean ± SEM.
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein a; HOMA-
IR, homeostasis model assessment-insulin resistance, hs-CRP, high-sensitivity C-reactive protein.43
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tients (23.1%) showed diastolic dysfunction on Doppler echo-
cardiographic studies. The characteristics of the patients with 
and without prevalent diastolic dysfunction are compared in 
Table 1. Patients with LV diastolic dysfunction were older than 
patients without LV diastolic dysfunction (60.0 ± 2.5 vs. 50.5 ± 
1.9 years; P < 0.01). There was no difference in the sex ratio 
between the two groups. After adjusting for age and sex, BMI 
was found to be higher (26.6 ± 0.7 vs. 24.6 ± 0.3 kg/m
2; P < 0.01) 
and diabetes duration was found to be longer (9.65 ± 1.48 vs. 
4.71 ± 0.78 years; P < 0.01) in patients with LV diastolic dysfunc-
tion than in those without LV diastolic dysfunction. There were 
no differences in smoking, blood pressure, lipid profiles, HbA1C, 
fasting plasma glucose, fasting serum insulin, or diabetic mi-
crovascular complications between the LV diastolic dysfunc-
tion group and the normal LV diastolic function group. There 
was no difference between the two groups in medications for 
hyperglycemia or dyslipidemia, including thiazolidinediones, 
statins, and insulin (data not shown).
Echocardiologic parameters
No subject had LV systolic dysfunction and no differences in 
LVEF were found between the LV diastolic dysfunction group 
and the normal LV diastolic function group (P = 0.18). The E/
A ratio was lower in patients with LV diastolic dysfunction (0.70 
± 0.04 vs. 1.07 ± 0.29; P < 0.001). There were no significant dif-
ferences in other parameters between the LV diastolic dysfunc-
tion group and the normal LV diastolic function group (Table 2).
Diabetes duration as an independent determinant for 
diastolic dysfunction
Logistic regression analysis for diastolic dysfunction with age, 
sex, BMI, and diabetes duration as covariates showed that dia-
betes duration and BMI were independent determinants (Table 
3). When participants were classified into four groups based 
on the duration of diabetes (≤ 1, >1 and ≤ 5, > 5 and ≤ 10, > 10 
years), the frequency of LV diastolic dysfunction increased with 
increasing duration of diabetes after adjusting for age, sex, and 
BMI (P for trend = 0.005; Fig. 1).
DISCUSSION
In the present study, we found that duration of diabetes was 
strongly associated with the presence of LV diastolic dysfunc-
tion in type 2 diabetic patients without hypertension or IHD. 
After adjusting for age, sex, and BMI, the frequency of LV dia-
Table 2.  Echocardiographic parameters







E/A ratio 1.07 ± 0.29 0.70 ± 0.04 <0.001
DT, ms 221.9 ± 53.8 238 ± 27.5 0.14
IVRT, ms 101.0 ± 44.9 120.7 ± 71.5 0.37
E’, cm/s 11.2 ± 2.7 10.4 ± 2.3 0.51
A’, cm/s 7.9 ± 2.3 8.1 ± 3.4 0.80
E/E’ ratio 8.5 ± 2.7 9.5 ± 3.0 0.25
LVEF, % 67.5 ± 4.2 65.5 ± 5.9 0.18
Data are expressed as mean ± SD.
E/A, the ratio of early and late left ventricular diastolic filling; DT, the 
E-wave deceleration time; IVRT, the isovolumic relaxation time; E’ 
the early diastolic velocity by Tissue Doppler at lateral mitral annulus; 
A’, the late diastolic velocity by Tissue Doppler at lateral mitral annu-
lus; E/E’, the ratio of E and E’; LVEF, left ventricular ejection fraction.
Table 3.  Logistic regression analysis of diastolic dysfunction 
in type 2 diabetic patients without hypertension with age, sex, 
BMI, and diabetes duration as covariates
Exp (B) (95% CI) P value
Age 1.04 (0.96 to 1.12) 0.385
Female 0.57 (0.09 to 3.75) 0.558
BMI 2.03 (1.21 to 3.41) 0.008
DM duration 1.39 (1.12 to 1.72) 0.003
BMI, body mass index; Exp (B), exponentiation of the B coefficient; 
DM, diabetes mellitus; CI, confidence interval.
Fig. 1.  Frequency of LV diastolic dysfunction according to di-
abetes duration in type 2 diabetic patients without hyperten-
sion, after adjusting for age, sex, and BMI. LV, left ventricular; 
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stolic dysfunction correlated positively with the duration of 
diabetes.
  Some previous studies demonstrated LV diastolic dysfunc-
tion in normotensive patients with diabetes, and the existence 
of LV diastolic dysfunction in the absence of coronary artery 
disease and hypertension has been ascribed to diabetic cardio-
myopathy [6-8]; however, there are very few studies on the fac-
tors associated with LV diastolic dysfunction in type 2 diabetes 
without hypertension or IHD. Aging and duration of diabetes 
were related to LV dysfunction in normotensive type 2 diabet-
ic patients in a previous study [9], which demonstrated a simi-
lar results of the present study.
  The proposed mechanisms of diabetic cardiomyopathy from 
animal studies are: i) excessive production of reactive oxygen 
species [16], ii) over-activation of poly-(ADP-ribose) polymer-
ase [17], iii) increased activity of protein kinase C [18], iv) dys-
functional calcium handling in cardiomyocytes [19], and v) 
enhanced activity of the renin-angiotensin-aldosterone system 
[20]. Several studies have suggested that hyperglycemia alters 
the metabolism of cardiac myocytes and could be the primary 
insult in the pathogenesis of diabetic cardiomyopathy [21,22]. 
Even in type 2 diabetic patients without cardiac involvement, 
uncontrolled hyperglycemia is known to provoke diastolic LV 
dysfunction [12,13]. Nichols et al. [23] demonstrated that a re-
duction in HbA1C coupled with a lower baseline HbA1C was 
predictive of a decreased incidence of heart failure in a multi-
variate model, emphasizing the importance of glycemic control 
for prevention of heart failure.
  Some data have suggested that diabetic cardiomyopathy 
could be one of the microvascular complications of diabetes 
related to endothelial dysfunction [21,24,25]. Considering that 
duration of diabetes is the strongest predictor for diabetic mi-
crovascular complications, the strong association of duration 
of diabetes with LV diastolic dysfunction observed in this study 
is plausible. In this study, the level of HbA1C was not associat-
ed with LV diastolic dysfunction, whereas diabetes duration 
was a significant determinant, suggesting that cumulative ex-
posure to hyperglycemia may be important for the development 
of LV diastolic dysfunction.
  Several studies have reported that obesity is associated with 
heart failure and ventricular dysfunction [26-29]. In a middle-
aged African-American cohort, obesity was associated with 
concentric hypertrophy, which was strongly associated with 
diastolic dysfunction [30]. Another study found that reduced 
LV diastolic function was apparent in 24% of severely obese 
subjects, and that the risk was linearly associated with BMI [29]. 
However, the association of obesity with diastolic dysfunction, 
independent of other causes, remains controversial [5,31]. From 
the results of this study, we suggest that obesity may be associ-
ated with LV diastolic dysfunction independent of other clini-
cal parameters related to diastolic dysfunction in type 2 diabet-
ic patients without hypertension or IHD.
  In this study, the prevalence of LV diastolic dysfunction was 
lower than in other studies [6-8], which could be because of 
the relatively short duration of diabetes, and our selection cri-
teria excluding patients with hypertension or IHD. We did not 
find a significant association of diabetic microvascular com-
plications such as retinopathy, nephropathy, and neuropathy 
with LV diastolic dysfunction, although frequencies of each 
microvascular complication tended to increase with the pres-
ence of LV diastolic dysfunction. This non-significant associa-
tion may be explained by the earlier development of diabetic 
cardiomyopathy compared with other microvascular compli-
cations [32-34], relatively well-controlled hyperglycemia, short 
duration of diabetes, and selection criteria excluding patients 
with hypertension or IHD.
  One limitation of our study is that it was cross-sectional and 
unable to suggest a causal relationship. Other limitations were 
the uncertainty of ischemic heart disease and diabetes duration. 
Our exclusion of IHD based on ECG and presence of symptoms 
might have not ruled out IHD completely. Besides, the onset 
of type 2 diabetes is not always clear, and previous medical re-
cords related to initial diagnosis were not available. Although 
the good correlation of diabetes duration with diabetic retin-
opathy (r = 0.516, P < 0.01) may lessen this concern, another 
prospective study for individuals with newly detected type 2 
diabetes is needed to confirm the results of our study.
  Despite the limitations of the study, our data showed that 
duration of diabetes could be a marker for LV diastolic dysfunc-
tion independent of other diastolic dysfunction-related vari-
ables in type 2 diabetic patients without hypertension or IHD.
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